The federal government’s Most-Favored-Nation (MFN) drug pricing initiative promises billions in potential savings, but will those lower manufacturer prices actually…
SHARx VP of Sourcing & Pharmacy Relations Otto Graham shares his perspective on prescription affordability and examines growing concerns among patients…
As employers face rising healthcare costs and difficult decisions surrounding GLP-1 medications heading into 2027, businesses must look beyond traditional…
SHARx CGO and co-founder Paul Pruitt shares his perspective on prescription affordability and healthcare access to a public-affairs audience interested…
SHARx CGO and co-founder Paul Pruitt highlights the continued importance of international pharmaceutical markets in helping Americans access affordable prescription…